drugset / Trial / NCT00233025

Duloxetine Versus Placebo in the Treatment of FMS

NCT00233025

Phase 3 Completed 320 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.

Timeline

Start
2005-09
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule

Indications